ASCO GU Conference Coverage
Featured Articles
(Curetoday.com) Feb 15, 2019 - The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as a frontline treatment for advanced renal cell carcinoma (RCC), according to Merck, the manufacturer of the anti-PD-1 therapy. “Many patients with advanced renal cell...
Read Article
(Pharmaphorum.com [UK]) Feb 15, 2019 - Bayer and development partner Orion have released detailed results from the trial that will form the backbone of its filing for their latest prostate cancer drug, as they aim to take on two established blockbusters from Johnson & Johnson and Pfizer/Astellas. J&J and Astellas market androgen...
Read Article
Latest Articles
February 15, 2019
February 15, 2019
February 15, 2019
February 15, 2019
February 15, 2019
February 15, 2019
February 14, 2019
February 14, 2019
View More
News Commentary
Editor Image
13 Feb, 2019 | by Tomasz M. Beer, MD
As contemporary hormonal agents are increasingly used earlier in prostate...
View Comment
Editor Image
05 Feb, 2019 | by Tomasz M. Beer, MD
Daralutamide would be the third agent with demonstrated efficacy in...
View Comment
View More
OBR Green
There are no ASCO GU Conference Coverage OBR Green articles.
Featured Videos
There are no ASCO GU Conference Coverage videos.
OBR Blog
As the Genitourinary Cancers (GU) Symposium gets under way in San Francisco February 13-16 2019, at a pre-meeting... Read more
February 11, 2019